Current Issue
Displaying 18 results:
Workshop report
Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV
Richard E Boehme, Stephen Cameron
Antiviral Therapy 2009; 14:1195-1208
Short communication
Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals
Ninon Taylor, Ilse Schmid, Alexander Egle, Richard Greil, Wolfgang Patsch, Hannes Oberkofler
Antiviral Therapy 2009; 14:1189-1193
Short communication
Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-α2a
Rami Moucari, Michelle Martinot-Peignoux, Vincent Mackiewicz, Nathalie Boyer, Marie-Pierre Ripault, Corinne Castelnau, Laurence Leclere, Agnes Dauvergne, Dominique Valla, Michel Vidaud, Marie-Hélène Nicolas-Chanoine, Patrick Marcellin
Antiviral Therapy 2009; 14:1183-1188
Short communication
Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina
Moira Vignoles, Graciela Barboni, María R Agosti, Jorge Quarleri, Mariel K García, Silvia González Ayala, Horacio Salomón
Antiviral Therapy 2009; 14:1175-1181
Original article
A randomized controlled trial of pegylated interferon-α2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B
Paola Piccolo, Ilaria Lenci, Luigi Demelia, Franco Bandiera, Maria R Piras, Giorgio Antonucci, Lorenzo Nosotti, Terenzio Mari, Adriano De Santis, Maria L Ponti, Orazio Sorbello, Fabio Iacomi, Mario Angelico
Antiviral Therapy 2009; 14:1165-1174
Original article
Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C
Ting-Hui Hsieh, Tai-Chung Tseng, Chun-Jen Liu, Ming-Yang Lai, Pei-Jer Chen, Hsin-Ling Hsieh, Ding-Shinn Chen, Jia-Horng Kao
Antiviral Therapy 2009; 14:1157-1163
Original article
Serum levels of surface large envelope proteins: prognostic markers for hepatitis B e antigen-negative patients with adefovir dipivoxil treatment
Xiao Fan, Dong Fang, Du Bin, Li Xueyong, Cheng Jun, Wei Hongshan
Antiviral Therapy 2009; 14:1149-1156
Original article
Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis
Serena Slavenburg, Ines Weggelaar, Martijn GH van Oijen, Joost PH Drenth
Antiviral Therapy 2009; 14:1139-1148
Original article
Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors
Karen Nieto, Andrea Kern, Barbara Leuchs, Lutz Gissmann, Martin Müller, Jürgen A Kleinschmidt
Antiviral Therapy 2009; 14:1125-1137
Original article
Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety
Sarah S Wilson, Natalia Cheshenko, Esra Fakioglu, Pedro MM Mesquita, Marla J Keller, Betsy C Herold
Antiviral Therapy 2009; 14:1113-1124